Bionano Genomics, Inc. (BMV:BNGO)
Mexico
· Delayed Price · Currency is MXN 57.00
0.00 (0.00%)
At close: Aug 13, 2025, 2:00 PM CST
Bionano Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Operating Revenue | 27.43 | 30.78 | 36.12 | 27.8 | 17.98 | 8.5 | Upgrade
|
| Revenue | 27.43 | 30.78 | 36.12 | 27.8 | 17.98 | 8.5 | Upgrade
|
| Revenue Growth (YoY) | -25.02% | -14.79% | 29.90% | 54.62% | 111.47% | -16.06% | Upgrade
|
| Cost of Revenue | 26.04 | 30.4 | 26.55 | 21.86 | 14.11 | 5.73 | Upgrade
|
| Gross Profit | 1.39 | 0.38 | 9.57 | 5.95 | 3.87 | 2.77 | Upgrade
|
| Selling, General & Admin | 38.59 | 51.86 | 94.22 | 86.48 | 56.92 | 29.57 | Upgrade
|
| Research & Development | 13.49 | 24.8 | 54.03 | 49.05 | 22.49 | 10.26 | Upgrade
|
| Operating Expenses | 52.08 | 76.66 | 148.25 | 135.53 | 79.41 | 39.82 | Upgrade
|
| Operating Income | -50.7 | -76.28 | -138.69 | -129.58 | -75.54 | -37.05 | Upgrade
|
| Interest Expense | -2.04 | -2.04 | -5.12 | -0.3 | -0.93 | -2.52 | Upgrade
|
| Interest & Investment Income | 1.17 | 2.1 | 3.31 | 1.51 | 0.24 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.06 | -4.69 | -15.38 | -0.12 | -0.06 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -49.5 | -80.9 | -155.87 | -128.5 | -76.29 | -39.58 | Upgrade
|
| Merger & Restructuring Charges | -2.18 | -8.02 | -0.74 | -1.8 | -1.5 | -1.5 | Upgrade
|
| Impairment of Goodwill | - | - | -77.28 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.1 | - | - | Upgrade
|
| Asset Writedown | -19.24 | -19.68 | - | - | - | - | Upgrade
|
| Other Unusual Items | -3.38 | -3.38 | 1.46 | -0.32 | -0.37 | - | Upgrade
|
| Pretax Income | -74.29 | -111.98 | -232.43 | -130.71 | -78.15 | -41.08 | Upgrade
|
| Income Tax Expense | 0.04 | 0.03 | 0.06 | 1.88 | -5.72 | 0.03 | Upgrade
|
| Net Income | -74.33 | -112.02 | -232.49 | -132.6 | -72.44 | -41.11 | Upgrade
|
| Net Income to Common | -74.33 | -112.02 | -232.49 | -132.6 | -72.44 | -41.11 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 1 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 183.33% | 123.37% | 18.05% | 4.49% | 165.50% | 596.04% | Upgrade
|
| EPS (Basic) | -32.25 | -88.13 | -408.60 | -275.09 | -157.02 | -236.58 | Upgrade
|
| EPS (Diluted) | -32.25 | -88.13 | -408.60 | -275.09 | -157.02 | -236.58 | Upgrade
|
| Free Cash Flow | -26.06 | -69.03 | -126.87 | -128.02 | -73.39 | -38.31 | Upgrade
|
| Free Cash Flow Per Share | -11.31 | -54.31 | -222.97 | -265.58 | -159.09 | -220.51 | Upgrade
|
| Gross Margin | 5.06% | 1.23% | 26.49% | 21.38% | 21.55% | 32.61% | Upgrade
|
| Operating Margin | -184.85% | -247.85% | -384.00% | -466.09% | -420.08% | -435.74% | Upgrade
|
| Profit Margin | -271.02% | -363.97% | -643.74% | -476.93% | -402.84% | -483.43% | Upgrade
|
| Free Cash Flow Margin | -95.03% | -224.28% | -351.29% | -460.46% | -408.14% | -450.59% | Upgrade
|
| EBITDA | -37.86 | -62.26 | -124.98 | -119.96 | -72.18 | -35.57 | Upgrade
|
| EBITDA Margin | -138.03% | -202.29% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 12.84 | 14.02 | 13.71 | 9.62 | 3.35 | 1.48 | Upgrade
|
| EBIT | -50.7 | -76.28 | -138.69 | -129.58 | -75.54 | -37.05 | Upgrade
|
| EBIT Margin | -184.85% | -247.85% | - | - | - | - | Upgrade
|
| Revenue as Reported | 27.43 | 30.78 | 36.12 | 27.8 | 17.98 | 8.5 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.